מכפיל מחיר לרווח Intra-Cellular Therapies Inc. (ITCI)

Intra-Cellular Therapies (ITCI) relies on predictable revenues from bipolar disorder and schizophrenia therapies, ensuring stable cash flows. The company's competitive advantages are guaranteed by robust patent protection and recognition within the professional psychiatric community. This price action chart on GURU.Markets shows a PE ratio of -185.50, driven by a sharp surge in profits from the sale of its primary drug and high investor expectations.

This metric is calculated as the ratio of market capitalization to net income, reflecting the sensitivity of business value to operational efficiency. This ratio measures the investment payback period based on current profitability. For Intra-Cellular Therapies (ITCI), it depends critically on Caplyta commercial sales and regulatory price caps. Any margin compression resulting from patent risks will be immediately reflected in the valuation. By analyzing the current P/E multiple, an investor can distinguish fundamental undervaluation from a systemic decline in revenue.